EGFR and esophageal squamous cell carcinoma: In this setting, we observe reactivation of ERK1/2 as an adaptive change after EGFR inhibition in EGFR-sensitive ESCC lines, similar to data seen in the study of EGFR inhibition of non-small-cell lung cancer29.